Brokerages predict that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will announce ($0.89) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aerie Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.96) and the highest is ($0.81). Aerie Pharmaceuticals reported earnings per share of ($0.62) in the same quarter last year, which would indicate a negative year over year growth rate of 43.5%. The company is scheduled to announce its next earnings report on Tuesday, May 1st.
On average, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($3.57) per share for the current year, with EPS estimates ranging from ($3.62) to ($3.52). For the next fiscal year, analysts forecast that the business will post earnings of ($1.65) per share, with EPS estimates ranging from ($2.15) to ($0.84). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Wednesday, February 28th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.21) by ($0.17).
A number of equities research analysts recently issued reports on AERI shares. Mizuho reissued a “buy” rating and issued a $87.00 target price on shares of Aerie Pharmaceuticals in a research report on Tuesday, December 19th. Canaccord Genuity set a $73.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 18th. Cantor Fitzgerald set a $77.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 18th. HC Wainwright initiated coverage on Aerie Pharmaceuticals in a research report on Friday, February 16th. They issued a “buy” rating and a $78.00 target price on the stock. Finally, Seaport Global Securities initiated coverage on Aerie Pharmaceuticals in a research report on Friday, January 26th. They set a “buy” rating and a $78.00 price target on the stock. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $78.75.
Aerie Pharmaceuticals stock traded down $2.00 during midday trading on Friday, reaching $50.25. The stock had a trading volume of 231,954 shares, compared to its average volume of 324,992. Aerie Pharmaceuticals has a 1-year low of $38.14 and a 1-year high of $66.60. The firm has a market cap of $1,984.52, a PE ratio of -14.91 and a beta of 0.95. The company has a debt-to-equity ratio of 0.91, a quick ratio of 10.09 and a current ratio of 10.09.
Large investors have recently bought and sold shares of the business. QS Investors LLC acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth approximately $125,000. Quantbot Technologies LP increased its position in shares of Aerie Pharmaceuticals by 792.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after purchasing an additional 2,647 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth approximately $176,000. Great West Life Assurance Co. Can increased its position in shares of Aerie Pharmaceuticals by 65.0% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after purchasing an additional 1,639 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. acquired a new position in shares of Aerie Pharmaceuticals during the 3rd quarter worth approximately $204,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “-$0.89 EPS Expected for Aerie Pharmaceuticals Inc (AERI) This Quarter” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/0-89-eps-expected-for-aerie-pharmaceuticals-inc-aeri-this-quarter.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.